Pharmacogenetic testing for guiding de novo phenprocoumon therapy in stroke patients

Cerebrovascular Diseases

Volumn 28, Issue 5, 2009, Pages 468-471

  Arnold, Marie Luise ^a   Grond Ginsbach, Caspar ^a   Kloss, Manja ^a   Di Mascio, Maria Teresa ^a   Veltkamp, Roland ^a   Ringleb, Peter ^a   Lichy, Christoph ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

De novo phenprocoumon treatment; Pharmacogenetic testing

Indexed keywords

OXIDOREDUCTASE; PHENPROCOUMON; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STROKE; TREATMENT RESPONSE;

AGED; ANTICOAGULANTS; FEMALE; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; PHENPROCOUMON; STROKE;

EID: 69749105006     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000235992     Document Type: Article

References (16)

1. Hart RG, Pearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
2. Engelter ST, Brandt T, Debette S, Caso V, Lichy C, Pezzini A, Abboud S, Bersano A, Dittrich R, Grond-Ginsbach C, Hausser I, Kloss M, Grau AJ, Tatlisumak T, Leys D, Lyrer PA: Antiplatelets versus anticoagulation in cervical artery dissection. Stroke 2007; 38: 2605-2611. (Pubitemid 47329646)
3. Bousser MG, Ferro JM: Cerebral venous thrombosis: an update. Lancet Neurol 2007; 6: 162-170.
4. Audebert HJ, Schenk B, Tietz V, Schenkel J, Heuschmann PU: Initiation of oral anticoagulation after acute ischaemic stroke or transient ischaemic attack: timing and complications of overlapping heparin or conventional treatment. Cerebrovasc Dis 2008; 26: 171-177.
5. Oldenburg J, Bevans CG, Fregin A, Geisen C, Muller-Reible C, Watzka M: Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC 1 and CYP2C9 alleles. Thromb Haemost 2007; 98: 570-578.
6. Oldenburg J, Watzka M, Rost S, Muller CR: VKORC1: molecular target of coumarins. J Thromb Haemost 2007; 5(suppl 1):1-6.
7. Oldenburg J, Marinova M, Muller-Reible C, Watzka M: The vitamin K cycle. Vitam Horm 2008; 78: 35-62.
8. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE: Effect of VKORC 1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293.
9. Millican EA, Lenzini PA, Milligan PE, Grosso L, Eby C, Deych E, Grice G, Clohisy JC, Barrack RL, Burnett RS, Voora D, Gatchel S, Tiemeier A, Gage BF: Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 2007; 110: 1511-1515.
10. Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V: The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost 2006; 95: 782-787.
11. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F: The impact of CYP2C9 and VKORC 1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood 2005; 106: 2329-2333.
12. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H: Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and interpopulation differences in maintenance dose of warfarin in Japanese, Caucasians and African- Americans. Pharmacogenet Genomics 2006; 16: 101-110.
13. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GY, Manning WJ: Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th edition). Chest 2008; 133: 546S-592S.
14. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM: Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999-1008.
15. Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, Muller CR, Wienker TF, Oldenburg J: VKORC1 haplotypes and their impact on the inter-individual and inter- ethnical variability of oral anticoagulation. Thromb Haemost 2005; 94: 773-779.
16. Georgiadis D, Arnold M, von Buedingen HC, Valko P, Sarikaya H, Rousson V, Mattle HP, Bousser MG, Baumgartner RW: Aspirin versus anticoagulation in carotid artery dissection: a study of 298 patients. Neurology 2009; 72: 1810-1815.